Skip to main content
An official website of the United States government
Email

cCRADA Collaborations for Nano-related Research and Development

The Nanotechnology Characterization Laboratory (NCL) has amassed a large knowledge base over its more than twenty years providing the Assay Cascade program. The NCL covers a multitude of nanoparticle platforms and biocompatibility data, characterization techniques, and their technical nuances. This knowledge is leveraged to provide sponsor-funded research and development for applications beyond the Assay Cascade’s constraints. It is carried out through a contractor, Cooperative Research and Development Agreement (cCRADA). While the Assay Cascade is restricted to characterization of oncology-based nanomedicines, cCRADA collaborations are not. cCRADA projects cover a broad range of research, including characterization of oncology or non-oncology nanomaterials, mechanistic studies, nanotech formulation projects, and more. NCL collaborates with each sponsor to create a tailored, highly customized research plan for each cCRADA project.

What We Offer

  • Formulation, optimization, lead selection: design and production of nanoformulations to achieve intended biological endpoints. Our staff has experience with small molecules, biologics, vaccines, and gene therapies.
  • Mechanistic studies: in vitro and in vivo studies to identify pharmacological or toxicological mechanisms.
  • Non-oncology nanomaterials: nanomedicines for other therapeutic indications; environmental, health, and safety characterization of engineered nanomaterials, etc.
  • Bioanalytical assay development: development and validation of assays for lot release, biological activity, bioequivalence, and more.
  • Instrument optimization: NCL works with instrument developers to improve analytical tools to best meet the needs of the nanotech research community.
  • And more… Contact us at ncl@mail.nih.gov to see how we can help.

cCRADA Process

cCRADA candidate projects are considered on a case-by-case basis throughout the year. We take several criteria into consideration, including optimal use of NCL’s capabilities and resources and alignment with NCL and NCI’s research interests. We also weigh a project's potential impact to improve nanomedicine research and development. Interested parties can email the NCL (ncl@mail.nih.gov) to discuss their project needs.

For approved projects, work is initiated through a cCRADA with Leidos Biomedical Research, Inc., the operations and technical support contractor for the Frederick National Lab.

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “cCRADA Collaborations for Nano-related Research and Development was originally published by the National Cancer Institute.”

Email